ライフサイエンスコーパス: saphenous vein

1 (e.g., 733 +/- 44 U/g of tissue at 6 hrs in saphenous vein).

2 11 for RA vs. ITA, and p < 0.001 for ITA vs. saphenous vein).

3 duced neointimal formation in cultured human saphenous vein.

4 e descended to the lower leg along the short saphenous vein.

5 panel graft constructed of recipient greater saphenous vein.

6 to those of the internal mammary artery and saphenous vein.

7 hich all others are compared--is the greater saphenous vein.

8 g-term patency of this conduit compared with saphenous vein.

9 ater than that of internal mammary artery or saphenous vein.

10 e was obtained with smooth muscle cells from saphenous vein.

11 s of normal human aorta, mammary artery, and saphenous vein.

12 m aortic and coronary artery, as well as the saphenous vein.

13 reoperation over single thoracic artery with saphenous vein.

14 smooth muscle cells were cultured from human saphenous vein.

15 for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.11 for RA vs. ITA, and p < 0.001 for I

16 ammary artery (6.2+/-0.3 pmol/mg protein) or saphenous vein (1.4+/-0.2 pmol/mg protein, both P<0.05).

17 ammary artery (3.5+/-1.3 pmol/mg protein) or saphenous vein (1.4+/-0.3 pmol/mg protein, both P<0.0001

18 er than internal mammary artery (56+/-9%) or saphenous vein (11+/-5%, both P<0.0001).

19 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted

20 %) than internal mammary artery (23+/-6%) or saphenous vein (5+/-2%, both P<0.05).

21 internal mammary artery (203+/-32 nmol/L) or saphenous vein (97+/-12 nmol/L, both P<0.05).

22 = 65 years) in mammary artery (no change in saphenous vein), accompanied by increased alpha(1b)>alph

23 that this axis behaves the same as the great saphenous vein after treatment.

24 that this axis behaves the same as the great saphenous vein after treatment.

25 reas internalization in large vessel EC from saphenous vein and aorta is rapid, like HUVEC.

26 Segments of saphenous vein and internal mammary artery and confluent

27 ynthase (eNOS) uncoupling were quantified in saphenous vein and internal mammary artery segments.

28 ivo release were quantified in perivascular (saphenous vein and internal mammary artery) subcutaneous

29 ent human smooth muscle cells, cultured from saphenous vein and internal mammary artery, were exposed

30 eceptors were shown to be expressed in human saphenous vein and internal mammary artery.

31 nd BH4 levels were determined in segments of saphenous vein and internal mammary artery.

32 imately 90% and 50% of cells in intact human saphenous vein and rat myocardium, respectively.

33 tylcholine and bradykinin were determined in saphenous veins and internal mammary arteries from 117 p

34 superoxide production was quantified in both saphenous veins and internal mammary arteries from 45 di

35 F, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained d

36 Samples of saphenous veins and internal mammary arteries were colle

37 sma and vascular biopterins (P<0.05 for both saphenous veins and internal mammary arteries).

38 In ex vivo experiments with human saphenous veins and internal mammary arteries, adiponect

39 3.8+/-0.8% in the internal mammary arteries, saphenous veins, and normal coronary arteries, respectiv

40 istance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studi

41 d during stenting in 22 patients with severe saphenous vein aorto-coronary bypass stenoses.

42 he angiographic patency of radial artery and saphenous vein aortocoronary bypass grafts at 5 years af

43 bosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion.

44 rimary, isolated CABG with the LITA, RA, and saphenous vein as needed.

45 been performed most often with the patient's saphenous vein as the conduit.

46 arameters of material obliterating the great saphenous vein at 7-21 days after polidocanol sclerother

47 nous enhancement (99 HU) was observed in the saphenous vein at the ankle, with all other venous stati

48 henous veins before organ culture and in pig saphenous veins before interposition grafting into carot

49 essed TIMP-3 at the luminal surface of human saphenous veins before organ culture and in pig saphenou

50 prophylactic therapy (testing hemostasis by saphenous vein bleeding 7 days after infusion of 150 IU/

51 he level of FVIIa needed for hemostasis in a saphenous vein bleeding assay.

52 Here, we use the saphenous vein bleeding model to compare the efficacy of

53 easured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with

54 ments from either internal mammary artery or saphenous vein, both forskolin and 8-Br-cAMP inhibited l

55 f 100 sternotomy CABG patients using IMA and saphenous veins, both treating equivalent number of targ

56 cantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but als

57 The use of aortic connectors for proximal saphenous vein bypass graft anastomoses eliminates the n

58 ting in the treatment of native coronary and saphenous vein bypass graft disease.

59 utaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs).

60 At angiography, 20 saphenous vein bypass grafts containing 19 connectors we

61 els and studies in patients (coronary artery saphenous vein bypass grafts, lesions of restenosis afte

62 me has been disappointing so far, except for saphenous vein bypass grafts.

63 and with graft stenosis and occlusion after saphenous vein bypass surgery.

64 ructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis

65 tion in patients with in-stent restenosis of saphenous-vein bypass grafts.

66 In segments of intact saphenous vein, C-type natriuretic peptide was significa

67 We determined whether human saphenous veins can be transduced with adenovirus vector

68 ase as the quest for an alternative graft to saphenous vein continues.

69 Results from a functional assay (rabbit saphenous vein contraction) demonstrate that certain dim

70 nts who underwent angioplasty of an occluded saphenous vein coronary artery bypass graft between Augu

71 Autologous saphenous vein coronary artery bypass graft surgery is c

72 that may prevent early and late occlusion of saphenous vein coronary bypass conduits.

73 complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but n

74 Degeneration of saphenous vein coronary bypass grafts has become a commo

75 nstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic reti

76 ine the effects of MARCKS silencing in human saphenous vein cultured ex vivo.

77 Compare the reparative potential of saphenous vein-derived pericytes (SVPs) with that of car

78 MT1-MMP expression in human saphenous vein-derived smooth muscle cells (SMCs) mainta

79 Primary cultures of human saphenous vein endothelial cells (ECs) and vascular smoo

80 ere incubated with IFN-gamma-activated human saphenous vein endothelial cells (HSVEC), but not with r

81 in bovine aortic endothelial cells and human saphenous vein endothelial cells in vitro and in adult m

82 to human erythroleukemia cells and to human saphenous vein endothelial cells was mediated by both al

83 Human saphenous vein endothelial cells were treated with ox-LD

84 ls of the hH1 isoform are expressed in human saphenous vein endothelium and that the presence of thes

85 In saphenous vein endothelium exposed to arterial flow cond

86 tion suppressed vascular remodeling of human saphenous vein explants ex vivo.

87 Limitations in the long-term patency of saphenous veins for bypass grafts have encouraged intere

88 Segments of internal mammary artery and saphenous vein from patients undergoing coronary artery

89 ve resulted in more favorable outcomes after saphenous vein graft (SVG) angioplasty.

90 stent implantation versus stenting alone for saphenous vein graft (SVG) aortoostial lesions.

91 The pattern of saphenous vein graft (SVG) calcification before percutan

92 aft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unk

93 t of creatine kinase (CK-MB) elevation after saphenous vein graft (SVG) intervention is high, its pro

94 use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studie

95 We sought to examine saphenous vein graft (SVG) lesions that fail within the

96 sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting ste

97 PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions.

98 et effect of aspirin, or both, contribute to saphenous vein graft (SVG) occlusion after coronary arte

99 pose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than 5

100 assess disease progression in nonintervened saphenous vein graft (SVG) segments to determine the nat

101 Treatment of saphenous vein graft (SVG) stenosis with percutaneous co

102 ectiveness of gamma-irradiation ((192)Ir) in saphenous vein graft (SVG) versus native coronary artery

103 20%) also received an RA graft instead of a saphenous vein graft (SVG).

104 cutaneous coronary intervention (PCI) of the saphenous vein graft (SVG).

105 25 women) underwent stenting of 212 vessels (saphenous vein graft [53%], left anterior descending cor

106 ) or conventional treatment (n = 395) in the Saphenous Vein Graft Angioplasty Free of Emboli Randomiz

107 Saphenous vein graft angioplasty has been limited by hig

108 g-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospecti

109 ient and SVG characteristics associated with saphenous vein graft atherosclerosis progression.

110 Angiographic changes in saphenous vein graft conduits 4.3 years after entry were

111 lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascu

112 bolysis in 39%, cardiogenic shock in 17% and saphenous vein graft culprit in 11% of patients.

113 e use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year pa

114 sis, bifurcation lesions, left main disease, saphenous vein graft disease, and acute coronary syndrom

115 ve coronary arteries, inhibit the process of saphenous vein graft disease, and improve vein graft pat

116 Aortocoronary saphenous vein graft disease, with its increasing clinic

117 tionship may also be seen after treatment of saphenous vein graft disease.

118 feration of the intima is an early lesion of saphenous vein graft disease.

119 High success was achieved in the saphenous vein graft group.

120 The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embo

121 When saphenous vein graft interventions were excluded, howeve

122 During saphenous vein graft interventions, particulate retrieve

123 essels, long coronary stenoses, and possibly saphenous vein graft interventions.

124 omes of embolic protection devices (EPDs) in saphenous vein graft interventions.

125 ative coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions (CAVEAT-II) were randomized

126 oronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increa

127 undergoing percutaneous intervention of 682 saphenous vein graft lesions were prospectively randomiz

128 ocation (78.6% in left main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesion

129 ercutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in

130 We recently demonstrated in a pig saphenous vein graft model that application of an extern

131 In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationship betwee

132 h platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass sur

133 In contrast, saphenous vein graft patency declined over time and simi

134 Trials that aspirin (325 mg daily) improves saphenous vein graft patency early (7 to 10 days) and at

135 ular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coro

136 We identified patients undergoing isolated saphenous vein graft percutaneous coronary intervention

137 tion or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention

138 s to improve outcomes among those undergoing saphenous vein graft percutaneous coronary intervention.

139 ic protection device use during contemporary saphenous vein graft percutaneous coronary intervention.

140 eft internal mammary artery), reperfusion B (saphenous vein graft perfusion).

141 Saphenous vein graft stenosis is a significant clinical

142 uardWire balloon or a vascular filter during saphenous vein graft stenting.

143 epeat revascularization than did multivessel saphenous vein graft stenting.

144 A saphenous vein graft to an important or less important t

145 otection filter devices during uncomplicated saphenous vein graft, carotid, renal, and superficial fe

146 nt vessel was randomized to radial artery vs saphenous vein graft.

147 ere administered into the coronary artery or saphenous vein graft.

148 hen the infarct-related vessel is a diseased saphenous vein graft.

149 of retrograde CTO PCI via patent or occluded saphenous vein graft.

150 The saphenous-vein graft is the most common conduit for coro

151 e center to have either the radial artery or saphenous vein grafted to a stenosed branch of the nativ

152 of patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with stents a

153 rteries (38.5%) and greater than that in new saphenous vein grafts (11.8%).

154 at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG cases) versus co

155 ternal mammary arteries (90.3%, P<0.0001) or saphenous vein grafts (64.0%, P=0.0016).

156 l conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001).

157 ernal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated i

158 EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and we

159 enosis rate of 15.1%, compared with 5.9% for saphenous vein grafts (P=0.0003) and 4.8% for left inter

160 atent radial artery grafts and 23% of patent saphenous vein grafts (P=0.01).

161 ception of patients treated with degenerated saphenous vein grafts (risk with placebo 16.3% vs. risk

162 This study defined long-term patency of saphenous vein grafts (SVG) and internal mammary artery

163 l outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predicto

164 iabetic patients after stent implantation in saphenous vein grafts (SVG).

165 S) for percutaneous coronary intervention in saphenous vein grafts (SVG).

166 Stenosis of saphenous vein grafts (SVGs) after coronary artery bypas

167 tomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing nat

168 Saphenous vein grafts (SVGs) are effective in relieving

169 Intimal hyperplasia of saphenous vein grafts (SVGs) can lead to subsequent graf

170 Because saphenous vein grafts (SVGs) exhibit greater cellular he

171 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been assoc

172 terial grafts have better patency rates than saphenous vein grafts (SVGs) in coronary artery bypass g

173 Approximately 15% of saphenous vein grafts (SVGs) occlude during the first ye

174 In each patient, all saphenous vein grafts (SVGs) placed (n = 11) with the de

175 Aortocoronary saphenous vein grafts (SVGs) undergo structural changes

176 s related to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based

177 ercutaneous coronary interventions (PCIs) in saphenous vein grafts (SVGs) with thrombus have a high f

178 coronary interventions (PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic prot

179 before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-densi

180 ruptured atherosclerotic plaques detected in saphenous vein grafts (SVGs).

181 ffects, is expressed in "arterialized" human saphenous vein grafts (SVGs).

182 of a high risk cohort treated with stents in saphenous vein grafts (SVGs).

183 ith the highest 10-year patency rate (>90%), saphenous vein grafts - the most commonly used conduit i

184 gnificantly better than the patency rate for saphenous vein grafts and comparable to reported patency

185 er superior long-term survival compared with saphenous vein grafts and should be considered in patien

186 erosclerotic progression among patients with saphenous vein grafts and that aggressive lipid lowering

187 nct to percutaneous intervention of diseased saphenous vein grafts and, compared with distal protecti

188 Saphenous vein grafts are exposed to hemodynamic stress

189 To achieve high success rate, use of saphenous vein grafts as retrograde conduits seems to be

190 nary stenting of stenoses in old (> 9 years) saphenous vein grafts can be successfully performed, wit

191 nt the latest evidence on the utilization of saphenous vein grafts for CABG surgery and provide an ov

192 rafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass graftin

193 The PercuSurge GuardWire was used in 17 saphenous vein grafts in 16 patients.

194 istal pore size 100 microns) were used in 47 saphenous vein grafts in 44 patients.

195 after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculat

196 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

197 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

198 Interventions were performed on either saphenous vein grafts or native vessels and utilized ang

199 enever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those

200 Implantation of saphenous vein grafts promotes upregulation of NADPH oxi

201 Saphenous vein grafts remain patent for approximately 10

202 rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending ve

203 Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypas

204 Saphenous vein grafts used in coronary artery bypass gra

205 ; 98.3% of radial artery grafts and 86.4% of saphenous vein grafts were patent (P=0.04).

206 l of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, usi

207 Early and late patency of saphenous vein grafts were similar in patients with and

208 year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus singl

209 ger vessels, in the right coronary artery or saphenous vein grafts, and for unfavorable lesion charac

210 during percutaneous coronary intervention of saphenous vein grafts, but the use of these devices in c

211 xus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent rest

212 anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent reste

213 ncy has been shown to be superior to that of saphenous vein grafts.

214 rates than left internal mammary artery and saphenous vein grafts.

215 reased the progression of atherosclerosis in saphenous vein grafts.

216 in-stent restenosis in native coronaries and saphenous vein grafts.

217 ors for a rapid atherosclerotic attrition of saphenous vein grafts.

218 the detrimental effect of atherosclerosis on saphenous vein grafts.

219 n may reduce the risk of early thrombosis in saphenous vein grafts.

220 rnal thoracic artery (ITA) grafts and 20,066 saphenous vein grafts.

221 , or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) fr

222 Treatment of stenosis in saphenous-vein grafts after coronary-artery bypass surge

223 of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse

224 omes in patients with obstructive disease of saphenous-vein grafts.

225 up reported significantly more pain than the saphenous vein group 3 months after surgery; however, si

226 (366 in the radial artery group, 367 in the saphenous vein group).

227 operative baseline between radial artery and saphenous vein groups after adjusting for covariates (P

228 utive patients with primary unilateral great saphenous vein (GSV) reflux undergoing endovenous treatm

229 e consequences of radial artery harvest with saphenous vein harvest in patients undergoing elective c

230 hundred forty-two patients with sternal and saphenous vein harvest wounds had half of each wound clo

231 factor (VWF) by immunofluorescence in great saphenous veins harvested at cardiac bypass surgery.

232 Use of endoscopic saphenous vein harvesting has developed into a routine s

233 The human saphenous vein has a greater propensity for intimal hype

234 -C protein was not detected in control human saphenous veins; however, it was uniformly and strongly

235 Standard harvest and preparation of human saphenous vein (HSV) for autologous coronary and periphe

236 ue with a cumulative manner in ex vivo human saphenous vein (HSV) model.

237 Aged, diseased, human saphenous vein (HSV) remnants obtained from patients und

238 n macrovascular endothelial cells from human saphenous vein (HSVEC).

239 ion of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated N

240 function in normal and atherosclerotic human saphenous vein imply a role for the peptide in the progr

241 Using human saphenous vein in a validated ex vivo flow circuit, we i

242 ides superior long-term patency rates to the saphenous vein in most situations.

243 gulator of acute endothelial inflammation in saphenous vein in response to acute arterial WSS.

244 reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after

245 ure base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolate

246 ophilia B mice, the times to first clot at a saphenous vein injury site after the infusions of the FI

247 the time to occlusion after FeCl(3)-induced saphenous vein injury.

248 was to assess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.

249 l of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial a

250 In ex vivo experiments with human saphenous veins/internal mammary arteries and adipose ti

251 f stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic

252 number of arterial grafts into the LIMA plus saphenous veins (LIMA/SV) group (n=7435) or the MultArt

253 cation to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia signif

254 The long saphenous vein (LSV) is commonly used as a conduit in co

255 Similar effects were observed in human saphenous vein medial segments where proliferation was r

256 F-positive MPs had increased thrombosis in a saphenous vein model.

257 mutation in FOXC2 showed reflux in the great saphenous vein (n=18), compared with only 1 of 12 refere

258 radial artery, internal mammary artery, and saphenous vein (n=24 patients) were examined by use of o

259 P)H oxidase activity was determined in human saphenous veins obtained from 110 patients with coronary

260 peroxide production were determined in human saphenous veins obtained from 133 patients with coronary

261 analysis had radial artery only (n = 80) or saphenous vein only (n = 337) harvest.

262 , and venous surgery not involving the great saphenous vein (OR = 15.61, P < 0.001).

263 - 0.2% for the RA, and 55.0 +/- 0.2% for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.1

264 s of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respective

265 atients enrolled in the Radial artery versus Saphenous Vein Patency (RSVP) trial.

266 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and

267 Patients with saphenous vein reflux undergoing treatment with endother

268 Adenovirus-mediated gene transfer to human saphenous veins resulted in functional transgene express

269 M, provokes sustained contractures in rabbit saphenous vein rings with greater efficacy than noradren

270 ility was evaluated by organ bath studies on saphenous vein rings.

271 rior descending artery, and radial artery or saphenous vein segments are used to graft the lateral an

272 l artery in vivo and by vasomotor studies in saphenous vein segments ex vivo.

273 nical significance was investigated by using saphenous vein segments from non-coronary heart disease

274 At operation, saphenous vein segments were explanted for VSMC culture.

275 growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the

276 We used deep RNA-sequencing of human saphenous vein SMCs stimulated with IL (interleukin)-1al

277 tudy, transient transfection assays in human saphenous vein smooth muscle cells (HSVSMC) and pulmonar

278 od or from adult peripheral blood, and human saphenous vein smooth muscle cells (HSVSMCs) as a source

279 n was increased in carotid atherectomies and saphenous vein specimens from diabetic versus nondiabeti

280 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

281 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

282 diabetic and nonischemic patients undergoing saphenous vein stripping were used.

283 on is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts.

284 operation: 2,389 had LITA grafting and 1,084 saphenous vein (SV) grafting to the LAD.

285 have significantly better patency rates than saphenous vein (SV) grafts at 5 years, but the physiolog

286 y artery, internal mammary artery (IMA), and saphenous vein (SV).

287 ight internal thoracic artery (RITA) and the saphenous vein (SV).

288 profiles of primary cultured ECs from human saphenous vein (SVEC) and coronary artery (CAEC) exposed

289 Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of card

290 Exposure of VSMCs derived from human saphenous vein to C pneumoniae EBs (3x10(7) inclusion fo

291 ncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following st

292 -derived growth factor-BB (PDGF-BB) in human saphenous vein VSMCs.

293 uccessful ablation of the main trunks of the saphenous vein was less common in the foam group than in

294 nsfers to inhibit intimal hyperplasia in the saphenous veins was evaluated.

295 Harvested segments of human saphenous vein were exposed for 1 hour at 37 degrees C t

296 Segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa

297 nts, segments of internal mammary artery and saphenous vein were obtained from five patients who rece

298 Segments of internal mammary artery and saphenous vein were obtained from patients undergoing co

299 reduced the adhesion of these cells to human saphenous vein, whereas PBM adhesion in the presence of

300 Adaptation of saphenous vein, with its intrinsic myogenic tone, from t